SARS-CoV-2 infection is a serious threat to human life and health all over the world,and COVID-19 is a global epidemic caused by SARS-CoV-2 infection.SARS-CoV-2 is highly infectious,strange and variable.Therefore,the ...SARS-CoV-2 infection is a serious threat to human life and health all over the world,and COVID-19 is a global epidemic caused by SARS-CoV-2 infection.SARS-CoV-2 is highly infectious,strange and variable.Therefore,the treatment of COVID-19 must be urgent and targeted.However,vaccines and currently used drugs generally do not have the above-mentioned characteristics.Although convalescent plasma of COVID-19 has shown a clinical application value in the emergency treatment of critical patients,it shows great limitations.All human recombinant multivalent neutralizing nano-antibodies may meet the deficiency of COVID-19 therapy.Gene engineering technologies have been used to develop specific neutralizing antibody(nAB)drugs for the treatment of COVID-19 worldwide.Some of the candidate nAB drugs have been entered the clinical trials and can be used for the therapy of COVID-19 shortly.In the present review,we studied and analyzed n ABs for the treatment of COVID-19 and the progress and prospect from the following five aspects:1)The biological and clinical characteristics of SARS-CoV-2 infection;2)The feasibility of plasma therapy for convalescents with COVID-19;3)The technical routes of developing n Ab drugs;4)The current status of developing global COVID-19 antibodies;5)The difficulties and clinical use.展开更多
基金China Postdoctoral Science Foundation(Grant No.2020T1300011ZX)National Science and Technology Major Project(Grant No.2018ZX10712001)Key Research and Development Projects of Tianjin Science and Technology Committee(Grant No.17YFZCSY00660)。
文摘SARS-CoV-2 infection is a serious threat to human life and health all over the world,and COVID-19 is a global epidemic caused by SARS-CoV-2 infection.SARS-CoV-2 is highly infectious,strange and variable.Therefore,the treatment of COVID-19 must be urgent and targeted.However,vaccines and currently used drugs generally do not have the above-mentioned characteristics.Although convalescent plasma of COVID-19 has shown a clinical application value in the emergency treatment of critical patients,it shows great limitations.All human recombinant multivalent neutralizing nano-antibodies may meet the deficiency of COVID-19 therapy.Gene engineering technologies have been used to develop specific neutralizing antibody(nAB)drugs for the treatment of COVID-19 worldwide.Some of the candidate nAB drugs have been entered the clinical trials and can be used for the therapy of COVID-19 shortly.In the present review,we studied and analyzed n ABs for the treatment of COVID-19 and the progress and prospect from the following five aspects:1)The biological and clinical characteristics of SARS-CoV-2 infection;2)The feasibility of plasma therapy for convalescents with COVID-19;3)The technical routes of developing n Ab drugs;4)The current status of developing global COVID-19 antibodies;5)The difficulties and clinical use.
